健脾解毒方通过调控HIF1α介导的成纤维细胞活化抑制结直肠癌生长
本研究探讨健脾解毒方(JPJDF)对结直肠癌(CRC)的治疗作用及分子机制。采用化学诱导小鼠CRC模型、网络药理学、分子对接、转录组学及CRC细胞与CCD-18Co成纤维细胞共培养体系,发现JPJDF可减少肿瘤体积而不影响体重,通过抑制HIF1α减少α-SMA表达和POSTN分泌,从而减弱成纤维细胞活化。HIF1α敲低抑制成纤维细胞增殖和克隆形成,过表达则促进。结论提示JPJDF通过靶向HIF1α抑制CAFs活化,为CRC治疗提供候选药物。
要点
- 健脾解毒方可减少化学诱导小鼠结直肠癌模型的肿瘤体积,且不影响体重。
- 健脾解毒方通过抑制HIF1α减少α-SMA表达和POSTN分泌,减弱成纤维细胞活化。
- HIF1α敲低抑制成纤维细胞增殖和克隆形成,过表达则促进。
核心结论
- 健脾解毒方通过靶向HIF1α抑制癌相关成纤维细胞活化,从而抑制结直肠癌生长。
研究设计与样本
- 采用UPLC-Q-TOF-MS鉴定健脾解毒方成分,建立化学诱导小鼠结直肠癌模型并给予健脾解毒方治疗。
- 运用网络药理学、分子对接和转录组学预测作用机制,并通过CRC细胞与CCD-18Co成纤维细胞共培养评估对成纤维细胞活化的影响。
- 采用CCK-8增殖、克隆形成和凋亡实验评估HIF1α对CAFs的作用,通过qPCR和Western blotting定量差异标志物表达。
主要发现
- 健脾解毒方减少化学诱导小鼠结直肠癌模型的肿瘤大小,且不影响体重,表明其安全性。
- 网络药理学结合分子对接和转录组学揭示健脾解毒方调控HIF-1信号通路,HIF1α为其抗CRC作用的潜在靶点。
- 健脾解毒方通过抑制HIF1α减少α-SMA表达和POSTN分泌,减弱成纤维细胞活化,从而在体内抑制CRC生长。
- CRC细胞中HIF1α敲低抑制成纤维细胞增殖和克隆形成,过表达则促进这些过程。
- 成纤维细胞中HIF1α下调抑制α-SMA和POSTN表达,过表达则增强成纤维细胞活化。
临床怎么用
- 健脾解毒方可作为靶向HIF1α抑制CAFs活化的候选治疗策略用于结直肠癌。
- 监测HIF1α及成纤维细胞活化标志物α-SMA和POSTN可能有助于评估健脾解毒方的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Jianpi Jiedu Formula (JPJDF) is a traditional Chinese medicinal decoction clinically used for its anti-cancer properties, particularly in colorectal cancer (CRC). AIM OF THE STUDY: This study aims to investigate the therapeutic effects of JPJDF on CRC and elucidate its potential molecular mechanisms, with a focus on its impact on hypoxia-inducible factor 1 alpha (HIF1α) and cancer-associated fibroblasts (CAFs) both in vitro and in vivo. MATERIALS AND METHODS: UPLC-Q-TOF-MS was used to identify the constituents of JPJDF. A chemical-induced colorectal cancer model was established and treated with JPJDF to evaluate its effects. Tumor size was measured, and histopathological analyses were performed to examine JPJDF's regulatory potential on CRC. The functional mechanism of JPJDF was predicted through network pharmacology, molecular docking, and transcriptomics. Co-culture techniques involving CRC cells and CCD-18Co fibroblasts were used to assess JPJDF's impact on fibroblast activation. The effects of HIF1α on CAFs were evaluated using CCK-8 proliferation, clonal formation, and apoptotic assays, with differential marker expression quantified via qPCR and Western blotting. RESULTS: Pharmacodynamic assessment demonstrated that JPJDF reduced tumor size without affecting body weight, indicating its safety in the chemical-induced murine CRC model. Network pharmacology analysis, combined with molecular docking and transcriptomics, revealed that JPJDF regulates HIF-1 signaling pathways and identified HIF1α as a potential target for JPJDF's anti-CRC effect. JPJDF effectively suppressed CRC growth in vivo by attenuating fibroblast activation, reducing α-SMA expression and POSTN secretion through HIF1α inhibition. HIF1α knockdown in CRC cells inhibited fibroblast proliferation and clonal formation, while overexpression promoted these processes. Additionally, downregulating HIF1α suppressed α-SMA and POSTN expression in fibroblasts, whereas overexpression enhanced fibroblast activation. CONCLUSION: JPJDF emerges as a promising therapeutic candidate for inhibiting CAFs activation by targeting HIF1α, offering potential avenues for modulating fibroblast activation towards CAFs in CRC therapy.
引用
- He S, Hao L, Chen Y, et al. Chinese herbal Jianpi Jiedu formula suppressed colorectal cancer growth in vitro and in vivo via modulating hypoxia-inducible factor 1 alpha-mediated fibroblasts activation. J Ethnopharmacol. 2024. PMID: 39209001. doi:10.1016/j.jep.2024.118753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。